Barry J. Goldstein
Division of Endocrinology
Diabetes and Metabolic Diseases
Jefferson Medical College of Thomas Jefferson University
Philadelphia
USA
Name/email consistency: high
- Are the metabolic effects of rosiglitazone influenced by baseline glycaemic control?. Goldstein, B.J., Cobitz, A.R., Hand, L.M., Chen, H. Curr. Med. Res. Opin (2003)
- Differentiating members of the thiazolidinedione class: a focus on efficacy. Goldstein, B.J. Diabetes Metab. Res. Rev. (2002)
- Protein-tyrosine phosphatases: emerging targets for therapeutic intervention in type 2 diabetes and related states of insulin resistance. Goldstein, B.J. J. Clin. Endocrinol. Metab. (2002)
- Insulin resistance as the core defect in type 2 diabetes mellitus. Goldstein, B.J. Am. J. Cardiol. (2002)
- Use of an Anaerobic Chamber Environment for the Assay of Endogenous Cellular Protein-Tyrosine Phosphatase Activities. Zhu, L., Goldstein, B. Biol. Proced. Online (2002)
- Protein-tyrosine phosphatase 1B (PTP1B): a novel therapeutic target for type 2 diabetes mellitus, obesity and related states of insulin resistance. Goldstein, B.J. Curr. Drug Targets Immune Endocr. Metabol. Disord. (2001)
- Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine phosphatase 1B. Possible facilitation by the formation of a ternary complex with the Grb2 adaptor protein. Goldstein, B.J., Bittner-Kowalczyk, A., White, M.F., Harbeck, M. J. Biol. Chem. (2000)
- Current views on the mechanism of action of thiazolidinedione insulin sensitizers. Goldstein, B.J. Diabetes Technol. Ther. (1999)









